Astellas Pharma (ALPMY) and Pfizer (PFE) announced longer-term follow-up results from an open-label extension of the Phase 3 ...

Astellas Pharma Inc. is a Japanese pharmaceutical company with a global presence. It has been engaged in the business of pharmaceutical products since 2004 and has established itself as a trusted name ...

Astellas Pharma Inc. (ALPMY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Astellas Pharma Inc. (ALPMY) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company ...

Thank you very much for joining our FY 2024 Financial Results Announcement Meeting by Astellas Pharma Inc. out of your very busy schedule today. I'm delighted to serve as a moderator. I'm Ikeda ...

The launch of PADCEV TM reinforces Astellas’ commitment to expanding its oncology portfolio in India. Following the introduction of Xospata TM (Gilteritinib) last April for relapsed or ...